Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age.

scientific article published on 19 October 2013

Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CCD.25189
P698PubMed publication ID24030753

P50authorFranz-Josef NeumannQ1308604
Adnan KastratiQ63253283
Karl-Ludwig LaugwitzQ63253454
Stefanie SchulzQ38590171
Robert A ByrneQ60607602
P2093author name stringGert Richardt
Salvatore Cassese
Gjin Ndrepepa
Massimiliano Fusaro
P2860cites workEffects of age on the quality of care provided to older patients with acute myocardial infarctionQ28195627
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyondQ29614697
Prediction of creatinine clearance from serum creatinineQ29615603
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrelQ33358562
Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trailQ34316739
Urban and rural dimensions of global population aging: an overviewQ34692807
The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarctionQ36162429
Clinical end points in coronary stent trials: a case for standardized definitionsQ36807166
Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patientsQ37538067
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research ConsortiumQ37889006
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trialQ38408523
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary interventionQ38500578
A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.Q40475543
Predictors of hospital mortality in the global registry of acute coronary eventsQ42611826
Comparison of outcomes in patients > or =70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndromeQ43287862
Enoxaparin versus unfractionated heparin in elective percutaneous coronary interventionQ44619428
The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromesQ45003891
Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrelQ45143057
Bivalirudin versus unfractionated heparin during percutaneous coronary interventionQ46429322
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end pointQ46750174
Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).Q47438826
Association between bleeding events and in-hospital mortality after percutaneous coronary intervention.Q50491796
Association between bleeding severity and long-term mortality in patients experiencing vascular complications after percutaneous coronary intervention.Q51407317
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.Q55055193
P433issue2
P304page(s)182-189
P577publication date2013-10-19
P1433published inCatheterization and Cardiovascular InterventionsQ2352240
P1476titleIncidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age.
P478volume83

Reverse relations

cites work (P2860)
Q93379484Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare
Q56384060Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease
Q38689160Coronary revascularisation in older patients with non-ST elevation acute coronary syndromes.
Q53335552Favorable outcomes in octogenarians treated with bioresorbable polymer drug-eluting stent.
Q47869639Inflammation and hemostasis in older octogenarians: implication in 5-year survival.
Q64277042Invasive strategy in elderly patients with acute coronary syndrome in 2018: close to the truth?
Q40478828Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.
Q41557516Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention
Q41265471Update on pharmacological treatment of acute coronary syndrome without persistent ST segment elevation myocardial infarction in the elderly

Search more.